666 related articles for article (PubMed ID: 28344808)
1. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer.
Hege KM; Bergsland EK; Fisher GA; Nemunaitis JJ; Warren RS; McArthur JG; Lin AA; Schlom J; June CH; Sherwin SA
J Immunother Cancer; 2017; 5():22. PubMed ID: 28344808
[TBL] [Abstract][Full Text] [Related]
2. Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA
Zhang C; Wang Z; Yang Z; Wang M; Li S; Li Y; Zhang R; Xiong Z; Wei Z; Shen J; Luo Y; Zhang Q; Liu L; Qin H; Liu W; Wu F; Chen W; Pan F; Zhang X; Bie P; Liang H; Pecher G; Qian C
Mol Ther; 2017 May; 25(5):1248-1258. PubMed ID: 28366766
[TBL] [Abstract][Full Text] [Related]
3. The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity.
Thistlethwaite FC; Gilham DE; Guest RD; Rothwell DG; Pillai M; Burt DJ; Byatte AJ; Kirillova N; Valle JW; Sharma SK; Chester KA; Westwood NB; Halford SER; Nabarro S; Wan S; Austin E; Hawkins RE
Cancer Immunol Immunother; 2017 Nov; 66(11):1425-1436. PubMed ID: 28660319
[TBL] [Abstract][Full Text] [Related]
4. Effective Targeting of TAG72
Murad JP; Kozlowska AK; Lee HJ; Ramamurthy M; Chang WC; Yazaki P; Colcher D; Shively J; Cristea M; Forman SJ; Priceman SJ
Front Immunol; 2018; 9():2268. PubMed ID: 30510550
[TBL] [Abstract][Full Text] [Related]
5. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
Wong JY; Chu DZ; Yamauchi D; Odom-Maryon TL; Williams LE; Liu A; Esteban JM; Wu AM; Primus FJ; Beatty JD; Shively JE; Raubitschek AA
J Nucl Med; 1998 Dec; 39(12):2097-104. PubMed ID: 9867150
[TBL] [Abstract][Full Text] [Related]
6. Genetically engineered T cells bearing chimeric nanoconstructed receptors harboring TAG-72-specific camelid single domain antibodies as targeting agents.
Sharifzadeh Z; Rahbarizadeh F; Shokrgozar MA; Ahmadvand D; Mahboudi F; Jamnani FR; Moghimi SM
Cancer Lett; 2013 Jul; 334(2):237-44. PubMed ID: 22902507
[TBL] [Abstract][Full Text] [Related]
7. Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases.
Magee MS; Abraham TS; Baybutt TR; Flickinger JC; Ridge NA; Marszalowicz GP; Prajapati P; Hersperger AR; Waldman SA; Snook AE
Cancer Immunol Res; 2018 May; 6(5):509-516. PubMed ID: 29615399
[TBL] [Abstract][Full Text] [Related]
8. [Advances of CAR-T cell therapy in treating colorectal cancer].
Chao Z; Liu W; Liu Y
Sheng Wu Gong Cheng Xue Bao; 2024 May; 40(5):1365-1379. PubMed ID: 38783803
[TBL] [Abstract][Full Text] [Related]
9. Interferon alpha enhances expression of TAG-72 and carcinoembryonic antigen in patients with primary colorectal cancer.
Mahvi DM; Madsen JA; Witt PL; Sondel PM
Cancer Immunol Immunother; 1995 May; 40(5):311-4. PubMed ID: 7600563
[TBL] [Abstract][Full Text] [Related]
10. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
[TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer.
Tchou J; Zhao Y; Levine BL; Zhang PJ; Davis MM; Melenhorst JJ; Kulikovskaya I; Brennan AL; Liu X; Lacey SF; Posey AD; Williams AD; So A; Conejo-Garcia JR; Plesa G; Young RM; McGettigan S; Campbell J; Pierce RH; Matro JM; DeMichele AM; Clark AS; Cooper LJ; Schuchter LM; Vonderheide RH; June CH
Cancer Immunol Res; 2017 Dec; 5(12):1152-1161. PubMed ID: 29109077
[TBL] [Abstract][Full Text] [Related]
13. Systemic administration of recombinant interferon alfa in carcinoma patients upregulates the expression of the carcinoma-associated antigens tumor-associated glycoprotein-72 and carcinoembryonic antigen.
Roselli M; Guadagni F; Buonomo O; Belardi A; Vittorini V; Mariani-Costantini R; Greiner JW; Casciani CU; Schlom J
J Clin Oncol; 1996 Jul; 14(7):2031-42. PubMed ID: 8683233
[TBL] [Abstract][Full Text] [Related]
14. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells.
Zhang Y; Zhang W; Dai H; Wang Y; Shi F; Wang C; Guo Y; Liu Y; Chen M; Feng K; Zhang Y; Liu C; Yang Q; Li S; Han W
Sci China Life Sci; 2016 Apr; 59(4):379-85. PubMed ID: 27009300
[TBL] [Abstract][Full Text] [Related]
15. Modification of cytokine-induced killer cells with folate receptor alpha (FRα)-specific chimeric antigen receptors enhances their antitumor immunity toward FRα-positive ovarian cancers.
Zuo S; Wen Y; Panha H; Dai G; Wang L; Ren X; Fu K
Mol Immunol; 2017 May; 85():293-304. PubMed ID: 28360017
[TBL] [Abstract][Full Text] [Related]
16. Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.
Ahmed N; Brawley VS; Hegde M; Robertson C; Ghazi A; Gerken C; Liu E; Dakhova O; Ashoori A; Corder A; Gray T; Wu MF; Liu H; Hicks J; Rainusso N; Dotti G; Mei Z; Grilley B; Gee A; Rooney CM; Brenner MK; Heslop HE; Wels WS; Wang LL; Anderson P; Gottschalk S
J Clin Oncol; 2015 May; 33(15):1688-96. PubMed ID: 25800760
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor activity of human T cells expressing the CC49-zeta chimeric immune receptor.
McGuinness RP; Ge Y; Patel SD; Kashmiri SV; Lee HS; Hand PH; Schlom J; Finer MH; McArthur JG
Hum Gene Ther; 1999 Jan; 10(2):165-73. PubMed ID: 10022542
[TBL] [Abstract][Full Text] [Related]
18. Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial.
Macey DJ; Grant EJ; Kasi L; Rosenblum MG; Zhang HZ; Katz RL; Rieger PT; LeBherz D; South M; Greiner JW; Schlom J; Podoloff DA; Murray JL
Clin Cancer Res; 1997 Sep; 3(9):1547-55. PubMed ID: 9815842
[TBL] [Abstract][Full Text] [Related]
19. CAR T Therapy Targeting ICAM-1 Eliminates Advanced Human Thyroid Tumors.
Min IM; Shevlin E; Vedvyas Y; Zaman M; Wyrwas B; Scognamiglio T; Moore MD; Wang W; Park S; Park S; Panjwani S; Gray KD; Tassler AB; Zarnegar R; Fahey TJ; Jin MM
Clin Cancer Res; 2017 Dec; 23(24):7569-7583. PubMed ID: 29025766
[No Abstract] [Full Text] [Related]
20. Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer.
Nagorsen D; Keilholz U; Rivoltini L; Schmittel A; Letsch A; Asemissen AM; Berger G; Buhr HJ; Thiel E; Scheibenbogen C
Cancer Res; 2000 Sep; 60(17):4850-4. PubMed ID: 10987297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
